Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
15:398–400 © 1997 Lippincott-Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume 15, 1997

Author Index

Adams SL, 257
Ahmed S, 88
Ajisawa A, 319
Albert J, 381
Al-Bisher AA, 88
Al-Hamdan S, 88
Al-Mufti S, 88
Anderson DJ, 185
Andersson S, 320, 381
Artenstein A, 304
Artenstein AW, 49
Aszalos A, 16
Avrett S, 165

Balfe P, 296
Balsari A, 61
Balzarini J, 1
Barber TW, 275
Baroncelli S, 5
Barrett DC, 318
Barry PA, 5
Baum MK, 370
Beijnen JH, 131
Bentwich Z, 296
Bertrand F, 387
Bessinger R, 341
Beyrer C, 304
Bhat A, 393
Biberfeld G, 320, 381
Birx DL, 49
Biti RA, 257
Black SB, 126
Blanche S, 121
Blattner W, 232
Blattner WA, 387
Blick G, 84
Blomberg J, 381
Blumberg BS, 387
Bogner JR, 192
Bracci P, 223
Branson BM, 312
Brathwaite AR, 232
Bucher HC, 104
Bulterys M, 76
Burgard M, 121
Burger DM, 131
Burns DN, 76
Busch MP, 145, 243
Byaruhanga R, 375

Canaris AD, 61
Cantalamessa A, 61
Capitanio JP, 5
Cardoso T, 177
Carr A, 176
Carruth A, 179
Caruso A, 61
Cassol SA, 49
Castillon M, 179
Catovsky D, 238
Chaix M-L, 121
Chang B-H, 204
Chang G, 49
Chang I, 21
Chaowanachan T, 391
Clark RA, 341
Coelho RCA, 238
Cohen CJ, 275
Cohen D, 126
Cohen MS, 54
Comeau AM, 35
Contreras R, 179
Cooper DA, 176
Cooper E, 204
Coovadia HM, 86
Cornelisse PGA, 115
Corral I, 175
Corulli M, 61
Coste J, 174
Coutsoudis A, 86
Craib KJP, 115
Crowe SM, 95

Dall L, 283
Dayhoff DE, 49
de Carvalho SMF, 238
De Clercq E, 1
De Francesco MA, 61
De Gasperi R, 83
de Oliveira MSP, 238
Declercq E, 387
Delamare C, 121
Delaporte E, 174
Denoyers H, 177
Deren S, 289
Dias F, 320
Diaz C, 198
Dietrich U, 296
Dolin R, 346
Donfield SM, 137
Dorenbaum A, 35
Doussin A, 121
Dubickas SH, 151
Dyer JR, 54

Efron B, 269
Eklund I, 381
Ellner JJ, 375
Engström A, 381
Eron JJ Jr 54
Estrada A, 289

Fallacara F, 61
Fernández-Ruiz LC, 175
Ferrari NA, 325
Figueroa JP, 232
Fiorentini S, 61
Fischl MA, 28
Fiscus SA, 54
Fleming D, 151
Fletcher MA, 83, 370
Flexner C, 28
Foldeak S, 16
Fowler MG, 204
Frank I, 283
Freedberg KA, 275
Freimuth WW, 54
French Pediatric HIV Infection Study Group, 121
Fujii S, 247
Fujimoto K, 247

Gail MH, 363
Garton T, 84
Gehring S, 296
Gertner JM, 137
Getty J, 392
Gilliam BL, 54
Gocke DJ, 283
Goebel FD, 192
Goedert JJ, 76, 363
Goldberg B, 176
Goldstein M, 289
González RG, 21

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
15:398–400 © 1997 Lippincott-Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume 15, 1997

Author Index

Adams SL, 257
Ahmed S, 88
Ajisawa A, 319
Albert J, 381
Al-Bisher AA, 88
Al-Hamdan S, 88
Al-Mufti S, 88
Anderson DJ, 185
Andersson S, 320, 381
Artenstein A, 304
Artenstein AW, 49
Aszalos A, 16
Avrett S, 165

Balfe P, 296
Balsari A, 61
Balzarini J, 1
Barber TW, 275
Baroncelli S, 5
Barrett DC, 318
Barry PA, 5
Baum MK, 370
Beijnen JH, 131
Bentwich Z, 296
Bertrand F, 387
Bessinger R, 341
Beyrer C, 304
Bhat A, 393
Biberfeld G, 320, 381
Birx DL, 49
Biti RA, 257
Black SB, 126
Blanche S, 121
Blattner W, 232
Blattner WA, 387
Blick G, 84
Blomberg J, 381
Blumberg BS, 387
Bogner JR, 192
Bracci P, 223
Branson BM, 312
Brathwaite AR, 232
Bucher HC, 104
Bulterys M, 76
Burgard M, 121
Burger DM, 131
Burns DN, 76
Busch MP, 145, 243
Byaruhanga R, 375

Canaris AD, 61
Cantalamessa A, 61
Capitanio JP, 5
Cardoso T, 177
Carr A, 176
Carruth A, 179
Caruso A, 61
Cassol SA, 49
Castillon M, 179
Catovsky D, 238
Chaix M-L, 121
Chang B-H, 204
Chang G, 49
Chang I, 21
Chaowanachan T, 391
Clark RA, 341
Coelho RCA, 238
Cohen CJ, 275
Cohen D, 126
Cohen MS, 54
Comeau AM, 35
Contreras R, 179
Cooper DA, 176
Cooper E, 204
Coovadia HM, 86
Cornelisse PGA, 115
Corral I, 175
Corulli M, 61
Coste J, 174
Coutsoudis A, 86
Craib KJP, 115
Crowe SM, 95

Dall L, 283
Dayhoff DE, 49
de Carvalho SMF, 238
De Clercq E, 1
De Francesco MA, 61
De Gasperi R, 83
de Oliveira MSP, 238
Declercq E, 387
Delamare C, 121
Delaporte E, 174
Denoyers H, 177
Deren S, 289
Dias F, 320
Diaz C, 198
Dietrich U, 296
Dolin R, 346
Donfield SM, 137
Dorenbaum A, 35
Doussin A, 121
Dubickas SH, 151
Dyer JR, 54

Efron B, 269
Eklund I, 381
Ellner JJ, 375
Engström A, 381
Eron JJ Jr 54
Estrada A, 289

Fallacara F, 61
Fernández-Ruiz LC, 175
Ferrari NA, 325
Figueroa JP, 232
Fiorentini S, 61
Fischl MA, 28
Fiscus SA, 54
Fleming D, 151
Fletcher MA, 83, 370
Flexner C, 28
Foldeak S, 16
Fowler MG, 204
Frank I, 283
Freedberg KA, 275
Freimuth WW, 54
French Pediatric HIV Infection Study Group, 121
Fujii S, 247
Fujimoto K, 247

Gail MH, 363
Garton T, 84
Gehring S, 296
Gertner JM, 137
Getty J, 392
Gilliam BL, 54
Gocke DJ, 283
Goebel FD, 192
Goedert JJ, 76, 363
Goldberg B, 176
Goldstein M, 289
González RG, 21

Greenberg SB, 283
Griffith L, 104
Guyatt GH, 104

Hahn JA, 157
Haimovici F, 185
Harrer E, 264
Harrer T, 264
Harrigan R, 86
Harrison LH, 308
Haubrich R, 28
Hayes K, 332
Hayes R, 232
Heath KV, 115
Hedberg K, 151
Hegerich P, 304
Hemophilia Growth and Development Study, 137
Hewlett I, 16
Higuchi H, 247
Hillyer GV, 204
Hoetelmans RMW, 131
Hofheinz D, 198
Hogg RS, 115
Holden-Wiltse J, 28
Holly EA, 211, 223
Hom DL, 375
Hopkins U, 84
Hudes ES, 318

Ishihara S, 70
Ivanoff S, 121

Janda W, 198
Johnson JL, 375
Julander I, 381
Juraszczyk J, 296

Kahn JO, 346
Kalden JR, 264
Kalish LA, 198
Kalish ML, 391
Käll K, 381
Karim A, 28
Kassler WJ, 312
Katzenstein D, 269
Kaufman FR, 137
Kazanji M, 177
Kececioglu J, 393
Kerndt PR, 179
Kessler H, 283
Khamboonruang C, 304
Khan C, 121
Kittinunvorakoon C, 391
Kityo C, 375
Klausner JD, 392
Koblin BA, 165
Koks CHW, 131
Kolodny EH, 83
Kraaijeveld CL, 131
Krook A, 381
Kunawararak P, 304
Kundu SK, 269

Lackner A, 21
LaGravinese L, 84
Lai H, 370
Lai S, 370
Landesman S, 76, 198
Lane J, 21
Lechat MF, 387
Lee S, 16
Lele C, 211, 223
Lerche NW, 5
Lew J, 198
Licenziati S, 61
Limata C, 126
Loughlin A, 375
Löw P, 264

Maayan S, 296
Magnan F, 177
Marcus C, 54
Markson LE, 88
Martin C, 381
Masjuan J, 175
Mason C, 304
Mastro TD, 391
Masuda G, 319
Mathes L, 332
Matsushita S, 247
Mayaux M-J, 121
Mayer KH, 185
McKinnis R, 283
Meehan PM, 28
Meenhorst PL, 131
Mendez H, 204
Mendez PJ, 320
Mendoza SP, 5
Merigan TC, 269
Mertz G, 283
Michael NL, 49
Mofenson L, 204
Molnar J, 16
Montaner JSG, 115
Montes B, 174
Moodley D, 86
Moodley J, 86
Moore MD, 283
Morikita T, 247
Morris J, 232
Mosley JW, 145, 243
Moss AR, 157
Moulton LH, 308
Moye J, 198
Mueller N, 70
Mugerwa RD, 375
Mugyenyi P, 375
Mulder JW, 131
Mulligan K, 43
Murai K, 70
Murphy RL, 283

Nadimpalli RG, 393
Nagatomo Y, 70
Natpratan C, 304
Navia B, 21
Nelson KE, 304
Newell M-L, 87
Ni H, 151
Nicolacakis K, 325

Obaru K, 247
Odem S, 179
Oglesbee M, 332
Okamoto H, 319
Okamoto M, 70
Okayama A, 70
Operskalski EA, 145, 243
Opravil M, 104
O'Shaughnessy M, 115
Ostrow MJ, 115
Otsyula M, 5

Page JB, 370
Para MF, 28
Patarca R, 83
Paul JP, 318
Pazzani MJ, 356
Pee D, 363
Peeters M, 174
Perez G, 283
Peruga A, 232
Peterman TA, 312
Petersen E, 283
Phair JP, 346
Pillay K, 86
Pine PS, 16
Pitt J, 198, 204
Podell M, 332
Polak S, 296
Pollard RB, 283

Quesenberry CP Jr, 126

Ramirez-Ronda C, 283
Rapier J, 391
Rayfield M, 391
Reis AM, 238
Reynes J, 174
Rich EA, 325
Rich KC, 198, 204
Richman DD, 28
Rimlawi A, 296
Rios M, 238
Rodrigues A, 320
Rodriguez RJ, 49
Rohwer P, 264
Rolinski B, 192
Rooney JF, 283
Rouzioux C, 121
Rubim LC, 238
Rubinstein A, 76
Rübsamen-Waigmann H, 296
Rungreungthanakit K, 304
Ruppach H, 296

Sadri I, 192
Sagawa K, 70
Sauberlich H, 370
Schambelan M, 43
Schechter M, 308
Schechter MT, 115
Schoen EJ, 126
Schroeder E, 356
See D, 356
Segarra C, 174
Segondy M, 174
Shaffer N, 391
Sharp M, 392
Shepp DH, 283
Sherer R, 283
Shibayama T, 319
Shima T, 70
Shor-Posner G, 370
Shrager DI, 387
Silva EM, 238
Silverman NS, 88
Sleeper LA, 137
Sönnerborg A, 381
Sorvillo F, 179
Sosa MAG, 83
Spino C, 269, 346
Stark M, 289
Stendahl P, 381
Stent G, 95
Stevens CE, 165
Stewart GJ, 257
Stone C, 86
Stram DO, 145, 243
Stricker RB, 176
Struve J, 381
Stuver S, 70
Suksaweang S, 391
Sullivan JL, 198
Svilar GM, 375

Tachibana N, 70
Tai VW, 43
Takatsuki K, 247
Talarmin A, 177
Tan W-Y, 363
Tanaka S, 319
Tao G, 312
Taylor EW, 393
Taylor PE, 165
Thuler LCS, 238
Tilles J, 356
Toossi Z, 325
Torok J, 151
Touraine J-L, 172
Tracey I, 21
Transfusion Safety Study Group, 145, 243
Tsubouchi H, 70
Turano A, 61
Turner BJ, 88

Überla K, 1

Valentine FT, 269
VanCott T, 304
Vardinon N, 296
Venkateswaran KS, 35
Vermund SH, 232
Vjecha M, 375
Voevodin A, 88
Vranizan KM, 157
Vyas GN, 35

Wara D, 35
Ward E, 232
Wathen L, 54
Weaver JL, 16
Weber C, 264
Williams M, 289
Wintergerst U, 192

Xia L, 325

Yang G, 35
Yeramian P, 28
Young N, 391
Yust I, 296

Zerhouni B, 172
Zhang G, 370
Zhang W, 393
Zhou S, 54

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
15:401–406 © 1997 Lippincott-Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume 15, 1997

Subject Index

Africa
  HTLV-I and HTLV-II in pregnant women in (letter), 320
  vaccine acceptability and HIV-1 risk in, 375
Age, in disease progression (letter), 243
AIDS, expert system in managing patients with, 356
AIDS dementia complex, in macaques, 21
Allergy, non-Hodgkin's lymphoma and, 211
Alveolar macrophages, activation of latent HIV-1 by *Mycobacterium tuberculosis* in, 325
3′-Amino-3′-deoxythymidine, penetration of into CSF of HIV-infected patients, 131
Amplicor HIV-1 polymerase chain reaction assay, modified (letter), 391
Anemia, with zidovudine treatment, 283
Antibody response, with SIV and cytomegalovirus coinfection, 5
Antigen expression, activation of in response to HIV-1-specific antigens, 61
Anti-HIV vaccine, acceptability of and HIV-1 risk, 375
Anti-Leu3a binding, in HIV infection inhibition, 16
Anti-opportunistic agents, determinants of complementary therapy use with, 115
Antiretroviral therapy
  CD8 T-cell response to (letter), 176
  determinants of complementary therapy use with, 115
  effect on HIV-1 viral burden in semen, 54
  in expert system for HIV management, 356
  phase I/II study of, 28
Antisulfatide IgG antibodies, recognizing HIV proteins (letter), 83
Azithromycin, for *Mycobacterium avium* complex infection prophylaxis, 275

Behavioral trends, in clients of sexually transmitted disease clinics, 151
Birth weight, adjustment for gestational age (letter), 87
Bisexual men, in HIV-1 vaccine efficacy trials, 165
Blood donors, prevalence of HTLV-I in (letter), 88
Blood specimens, from home collection kits, 312
Bloodborne infection, risk factors for in injecting drug users, 381
Blood-cerebrospinal fluid barrier, zidovudine pharmacokinetics and, 192
Body cell mass, cross-sectional and longitudinal evaluation in men with HIV infection, 43
Body composition, cross-sectional and longitudinal evaluation in men with HIV infection, 43
Brazil, HTLV-I and HTLV-II infection in, 238

Cachexia, in men with HIV infection, 43
Canada, complementary therapy use in HIV-infected patients in, 115
Cancer, HTLV-I and HTLV-II infection in, 238
Case-control studies, of non-Hodgkin's lymphoma in homosexual men, 211, 223
CD25 cell, in advanced HIV-1 infection, 61
CD71 cell, in advanced HIV-1 infection, 61
$CD4^+$ cell, rate of change of, 145
CD4 cell, recombinant soluble, 95
CD4 cell count, predictors of survival in HIV-infected persons and, 346
CD80 cell expression, on monocytes in HIV infection, 264
$CD4^+$ count
  in disease progression (letter), 243
  with HTLV-I/HIV-1 coinfection, 308
CD8 T-cell response, to antiretroviral therapy (letter), 176
CD4/CD8 lymphocyte ratio, in progressive encephalopathy in adult FIV-infected cats, 332
$CD8^+DR^+$ cell, in HIV-infected infants, 204
Cellular immune response, therapeutic HIV vaccination and, 269
Central nervous system, zidovudine pharmacokinetics in, 192
Cerebrospinal fluid
  AMT penetration into, 131
  zidovudine pharmacokinetics in, 192
Cervix, HIV-1 specific immunoglobulin antibodies in secretion of, 185
Chlorpromazine derivatives, HIV infection inhibition by, 16
Cidofovir, in AIDS-related cytomegalovirus retinitis, encephalitis, and esophagitis (letter), 84
Clarithromycin, for *Mycobacterium avium* complex infection prophylaxis, 275
Cloning, in expert system for HIV management, 356
Cofactors, cytomegalovirus and SIV, 5
Coinfection
  $CD4^+$ count and HIV viral load with, 308
  of GB virus C with HIV-1 (letter), 318
Complementary therapy, determinants of with antiretroviral or anti-opportunistic agents, 115
Compliance, with prenatal HIV testing in large HMO, 126

Congo, Democratic Republic of, survival of HTLV-I carriers in leprosy patients in, 387
Cost-effectiveness analysis, of *Mycobacterium avium* complex infection prophylaxis, 275
Cytomegalovirus, with SIV coinfection, 5
Cytomegalovirus retinitis, cidofovir in treating (letter), 84

Dapsone, in *Pneumocystis carinii* pneumonia and toxoplasma encephalitis prophylaxis, 104
Dementia, survival of HIV in older women and, 341
Diagnosis
  HIV-1 detection in neonatal plasma, 121
  immune complex-dissociated p24 antigen in assessing, 198
Dietary therapy, with antiretroviral or anti-opportunistic agents, 115
Dioxo-chloropromazine, in HIV infection inhibition, 16
Disease progression
  age, viral load, and $CD4^+$ count in (letter), 243
  with cytomegalovirus and SIV coinfection, 5
  of primary and chronic HIV-1 infection, 49
  with same or different HIV-1 strains, 145
Dose interval, for zidovudine, 283

Electroencephalography, in progressive encephalopathy in adult FIV-infected cats, 332
Encephalitis, cidofovir in treating (letter), 84
Encephalopathy, progressive, associated with CD4/CD8 inversion in adult FIV-infected cats, 332
Environmental exposures, in non-Hodgkin's lymphoma, 223
Epidemiology
  of HIV-1 in gay and bisexual men, 165
  of HIV in Israel, 296
  of HIV-1 in male sex workers in Thailand, 304
  of HTLV-II infection in injecting drug users, 381
Erratum
  Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate adult and adolescent spectrum of disease project (14:374), 94
Esophagitis, cidofovir in treating (letter), 84
Evoked potentials, in progressive encephalopathy in adult FIV-infected cats, 332
Expert system, application in management of HIV infection, 356

Feline immunodeficiency virus (FIV), progressive encephalopathy in, 332
Flow cytometry
  in detecting proviral DNA in infants, 35
  for T cells in advanced HIV-1 infection, 61
French Guiana, HIV-1 infection risk factors in pregnancy women in (letter), 177

Gag peptides, optimized culture conditions for detecting responses to, 257
GB virus C, coinfection with HIV-1 (letter), 318
Genetic diversity, quantification of HIV-1 RNA in plasma and (letter), 174
Genital tract secretion, HIV-1 specific immunoglobulin antibodies in, 185
Gestational age, birth weight adjustments for (letter), 87
Glutathione peroxidase, selenium-dependent (letter), 393
gp120, recombinant, in LFA-1 surface expression, 95
gp160 HIV-1 vaccine, viral load and, 269
gp41 sequence, HIV-1 infection encoding sequence overlapping (letter), 393
Granulocyte-macrophage colony-stimulating factor, in LFA-1 surface expression, 95
Growth factors, in HIV-positive vs. HIV-negative hemophilic males, 137
Growth hormone, in HIV-positive vs. HIV-negative hemophilic males with abnormal growth and pubertal development, 137
Guinea-Bissau, HTLV-I and HTLV-II in pregnant women in (letter), 320

Health maintenance organizations, compliance with voluntary prenatal HIV testing in, 126
Hematologic disorders, HTLV-I and HTLV-II infection in, 238
Hemophilia
  growth hormone secretion in HIV-positive vs. HIV-negative males with, 137
  survival after AIDS diagnosis with, 363
Hepatitis, risk factors for in injecting drug users, 381
Herbal therapy, with antiretroviral or anti-opportunistic agents, 115
HIV. *See* Human immunodeficiency virus
HIV-1 infection
  activation of by *Mycobacterium tuberculosis* and purified protein derivatives, 325
  AMT penetration into CSF in, 131
  characterization of proviral DNA in long-term, nonprogressive, 247
  coinfection with GB virus C (letter), 318
  effects on surface expression of LFA-1 on cultured monocytes, 95
  encoding sequence overlapping *env* gp41 in (letter), 393
  factors in progression of to AIDS (letter), 243
  genetic diversity of, effect on HIV-1 RNA quantification in plasma (letter), 174
  IgG, IgA, and IgM antibodies to in genital tract secretions, 185
  progression of with same or different strains, 145
  quantitative microculture, for viral burden in semen, 54
  reverse transcriptase gene of, 1
  risk factors among pregnant women in French Guiana (letter), 177
  serum and plasma viral RNA measurements in, 49
  transmission in infants of seropositive mothers, 35
  vertical transmission of, 76
  viral burden in semen with, 54
  vitamin A supplementation effect on viral load of in pregnant women (letter), 86
HIV-1 protease inhibitor, phase I/II study of, 28
HIV protein, antisulfatide IgG antibodies recognition of (letter), 83
HIV reverse transcriptase inhibitor, in LFA-1 surface expression, 95

HIV-1 RNA
detection in plasma for diagnosis of neonatal infection, 121
in disease progression, 145
HIV-1 genetic diversity and quantification of (letter), 174
in semen, 54
HIV-1 subtypes, in Israel, 296
HIV testing
home collection kits for, 312
trends in STD clinics, 151
HIV vaccine, acceptability of and HIV-1 risk, 375
HIV-1 vaccine efficacy trials, willingness to participate in among gay and bisexual men, 165
HIV-1/HTLV-I coinfection, HIV viral load and $CD4^+$ lymphocyte counts with, 308
Home collection kits, for HIV testing, 312
Homosexual men
in HIV-1 vaccine efficacy trials, 165
non-Hodgkin's lymphoma in
environmental exposures and, 223
medical and social factors in, 211
Hormone replacement therapy, survival of HIV in older women and, 341
Host factors, in HIV-1 progression, 145
HTLV. *See* Human T-cell lymphotropic virus
Human immunodeficiency virus
body composition evaluation in men with, 43
CD80 expression on monocytes in, 264
counseling for, trends in STD clinics, 151
early infection with, 204
expert system in managing patients with, 356
incidence among STD clinic clients in Jamaica, 232
inhibition of by chlorpromazine derivatives, 16
intergenerational linkage of (letter), 318
prenatal testing for in HMOs, 126
prophylaxis against *Pneumocystis carinii* pneumonia and toxoplasma encephalitis in, 104
serostatus, predictors of in out-of-treatment male drug users, 289
subtypes among male sex workers in Thailand, 304
Human T-cell lymphotropic virus
type I (HTLV-I)
decreased survival of carriers in leprosy patients, 387
in hematologic disorder, cancer and healthy patients, 238
incidence among STD clinic clients in Jamaica, 232
in pregnant women in Guinea-Bissau, West Africa (letter), 320
prevalence among blood donor volunteers in Kuwait (letter), 88
tax/rex-encoded mRNA of, 70
type II (HTLV-II)
in hematologic disorder, cancer and healthy patients, 238
in pregnant women in Guinea-Bissau, West Africa (letter), 320
prevalence and risk factors of in injecting drug users in Stockholm, 381
Human T-cell lymphotropic virus (HTLV-I)/HIV-1 coinfection, HIV viral load and $CD4^+$ lymphocyte counts with, 308
Hypersensitivity, non-Hodgkin's lymphoma and, 211

IgG antibodies, antisulfatide (letter), 83
Immune complex-dissociated p24 antigen, in congenital or perinatal HIV infection assessment, 198
Immune response
in advanced HIV-1 infection, 61
gp160 HIV-1 vaccine effect on, 269
Immunoglobulins, HIV-1 specific, in genital tract secretions, 185
Immunology, allergy and, 211
Immunoreactive bead assay, detecting proviral DNA in infants, 35
Infants
elevated $CD8^+DR^+$ lymphocytes in, 204
HIV-1 infection transmission to, 35
immune complex-dissociated p24 antigen in assessing HIV infection in, 198
Injection drug use
as predictor of HIV serostatus in out-of-treatment male drug users, 289
vertical transmission of HIV-1 and, 76
Injection drug users
HIV serostatus of, 289
prevalence of and risk factors for HTLV-II infection in, 381
in treatment, 157
Interleukin-2 receptor, increased expression on peripheral blood mononuclear cells in HTLV-I mRNA, 70
Intrapartum transmission, elevated $CD8^+DR^+$ lymphocytes and, 204
Intrauterine transmission, elevated $CD8^+DR^+$ lymphocytes as marker in, 204
Israel, molecular epidemiology of HIV in, 296

Jamaica, HIV and HTLV-I incidence in STD clinic clients in, 232
Japan, coinfection of GB virus C with HIV-1 in (letter), 318

Kuwait, prevalence of HTLV-I in blood donor volunteers in (letter), 88

Laboratory diagnosis, of HIV-1 infection in infants, 35
Lean body mass, cross-sectional and longitudinal evaluation in men with HIV infection, 43
Leprosy, HTLV-I carriers in, 387
Letters to editor
antisulfatide IgG antibodies recognize HIV proteins, 83
birth weight adjustments for gestational age, 87
CD8 T-cell responses to antiretroviral therapy, 176
coinfection of GB virus C with HIV-1 in Japan, 319
effect of HIV-1 genetic diversity on HIV-1 RNA quantification in plasma: comparative evaluation of three commercial assays, 174
effects of vitamin A supplementation on viral load in HIV-1-infected pregnant women, 86
HIV-1 encodes a sequence overlapping *env* gp41 with highly significant similarity to selenium-dependent glutathione peroxidases, 393
HIV-specific cytotoxic T lymphocytes in persons exposed

through sexual contact with HIV-infected patients, 172
HTLV-I and -II infections in a nationwide survey of pregnant women in Guinea-Bissau, West Africa, 320
influences of age, viral load, and $CD4^+$ count on the rate of progression of HIV-1 infection to AIDS, 243
modified amplicor HIV-1 polymerase chain reaction assay in Thailand, 391
mycobacterial acute lumbosacral polyradiculopathy as the initial manifestation of AIDS, 175
prevalence of human T-cell lymphotropic virus type I infection among volunteer blood donors in Kuwait, 88
reexamination of intergenerational linkage of HIV infection, 318
risk factors for HIV-1 infection among pregnant women in French Guiana, 177
successful use of cidofovir in treating AIDS-related cytomegalovirus retinitis, encephalitis, and esophagitis, 84
thalidomide use is associated with weight gain in HIV-1-positive clients, 392
use of protease inhibitors among persons with AIDS in Los Angeles County, 179
LFA-1 expression, HIV-1 effects on in cultured monocytes, 95
Lifestyle, non-Hodgkin's lymphoma and, 211
Long-term nonprogressors, proviral DNA in, 247
Los Angeles, protease inhibitors in AIDS patients in (letter), 179
Lymphoma, non-Hodgkin's
environmental exposures affecting in homosexual men, 223
medical and social factors for in HIV-positive and -negative homosexual men, 211

Magnetic resonance spectroscopy, revealing neuronal injury in SIV macaque model, 21
Malnutrition, in men with HIV infection, 43
Mental illness, survival of HIV in older women and, 341
Mental relaxation techniques, with antiretroviral or anti-opportunistic agents, 115
Meta-analysis, of *Pneumocystis carinii* pneumonia and toxoplasma encephalitis prophylaxis, 104
Molecular epidemiology
of HIV in Israel, 296
of HIV-1 in Thailand, 304
Monocytes
CD80 expression on, 264
HIV-1 effects on LFA-1 surface expression in, 95
Mortality
in AIDS diagnosis in hemophilia cohort, 363
HIV-related, with selenium deficiency, 370
Mycobacterial acute lumbosacral polyradiculopathy, as initial manifestation of AIDS (letter), 175
Mycobacterium avium complex infection, prophylaxis for in AIDS patients, 275
Mycobacterium tuberculosis, in activation of latent HIV-1, 325

Needle exchange, who uses, 157
Neonate, plasma HIV-1 RNA detection in, 121
Neuronal injury, in SIV macaque model, 21
Nucleic acid sequence-based amplification (NASBA) assay
for HIV-1 viral burden in semen, 54
in plasma HIV-1 RNA detection in neonatal infection, 121
Nutrition, in HIV-related mortality, 370

Occupational exposures, in non-Hodgkin's lymphoma, 223

p24 antigen, immune complex-dissociated in congenital or perinatal HIV infection assessment, 198
Pediatric AIDS, HIV-1 infection transmission and, 35
Pentamidine, aerosolized, in *Pneumocystis carinii* pneumonia and toxoplasma encephalitis prophylaxis, 104
Peptide enzyme immunoassay, for HIV in Israel, 296
Perinatal transmission
elevated $CD8^+DR^+$ lymphocytes as marker in, 204
immune complex-dissociated p24 antigen in assessing, 198
with seropositive mothers, 35
Pharmacokinetics, of zidovudine in cerebrospinal fluid, 192
Plasma
HIV-1 genetic diversity and quantification of HIV-1 RNA in (letter), 174
HIV-1 RNA detection in for diagnosis of neonatal infection, 121
RNA in, therapeutic HIV vaccination effect on, 269
Pneumocystis carinii pneumonia, prophylaxis against, 104
Polymerase chain reaction assay
in expert system for HIV management, 356
in measuring viral RNA in HIV-1 infection, 49
modified Amplicor (letter), 391
in proviral DNA detection in infants, 35
proviral DNA isolation by, 247
Polyradiculopathy, mycobacterial acute lumbosacral, as initial manifestation of AIDS (letter), 175
Pregnancy
HIV-1 infection risk factors during (letter), 177
HTLV-I and HTLV-II during (letter), 320
infectious complications of, 126
sexual behavior and injection drug use during, 76
vitamin A supplementation effect on viral load in (letter), 86
Prenatal HIV testing, compliance with in large HMO, 126
Prevention, of *Pneumocystis carinii* pneumonia and toxoplasma encephalitis in HIV infection, 104
Prognosis, with hemophilia, 363
Prognostic factors, in HIV survival, 346
Project ACHIEVE, 165
Prophylaxis
for disseminated *Mycobacterium avium* complex infection, 275
against *Pneumocystis carinii* pneumonia and toxoplasma encephalitis in HIV-infected patients, 104
Prostitution, molecular epidemiology of HIV-1 and, 304
Protease inhibitors, in AIDS patients in Los Angeles County (letter), 179
Proviral DNA
characterization in long-term, nonprogressive HIV-1 infection, 247
therapeutic HIV vaccination effect on, 269

Puberty, growth hormone secretion in HIV-positive vs. HIV-negative hemophilic males during, 137
Purified protein derivatives, in activation of latent HIV-1, 325
Pyrimethamine, in *Pneumocystis carinii* pneumonia and toxoplasma encephalitis prophylaxis, 104

Reverse transcriptase gene, ISV/HIV-1 hybrid virus expressing, 1
Reverse transcriptase inhibitors
  effect on HIV-1 viral burden in semen, 54
  of HIV-1, 1
Reverse transcriptase-polymerase chain reaction
  in activation of latent HIV-1 by *Mycobacterium tuberculosis*, 325
  in expert system for HIV management, 356
Rhesus macaques, neuronal loss with SIV infection in, 21
Rifabutin, for *Mycobacterium avium* complex infection prophylaxis, 275
Risk behaviors, in injection drug users, 157
Risk factors, for HTLV-II infection in injecting drug users, 381
RNA
  measurement in primary and chronic HIV-1 infection, 49
  sequencing of in expert system for HIV management, 356

SC-52151, phase I/II study of, 28
Selenium deficiency, in HIV-related mortality, 370
Self-emulsifying drug delivery system (SEDDS), for HIV protease inhibitor, 28
Semen
  effects of reverse transcriptase inhibitor on viral burden in, 54
  HIV-1 specific immunoglobulin antibodies in, 185
Seroconversion
  in injection drug users, 157
  in primary and chronic HIV-1 infection, 49
Serology, of SIV and cytomegalovirus coinfection, 5
Seropositive mothers, HIV-1 infection transmission to infants of, 35
Seroprevalence, in Ugandan military, 375
Sex workers, male, molecular epidemiology of HIV-1 in, 304
Sexual behavior
  of clients of sexually transmitted disease clinics, 151
  non-Hodgkin's lymphoma and, 211
  vertical transmission of HIV-1 and, 76
Sexual contact, HIV-specific cytotoxic T lymphocytes and (letter), 172
Sexual orientation, as predictor of HIV serostatus in out-of-treatment male drug users, 289
Sexually transmitted disease clinics
  HIV and HTLV-I incidence in, 232
  trends in HIV counseling and testing in, 151
Simian immunodeficiency virus
  with cytomegalovirus coinfection, 5
  neuronal loss with in macaques, 21
Simian immunodeficiency virus (SIV)/HIV-1 hybrid virus, expressing reverse transcriptase gene of HIV-1, 1
SIV. *See* Simian immunodeficiency virus
South America, HIV-1 infection risk factors in pregnancy women in (letter), 177
Stockholm, prevalence of and risk factors for HTLV-II infection in injecting drug users of, 381
Survival
  after AIDS diagnosis in hemophilia cohort, 363
  clinical manifestations and predictors of in older HIV-infected women, 341
  of HTLV-I carriers in leprosy patients, 387
  predictors of in HIV-infected persons with 50 or fewer CD4 cells/mm^3, 346
Sweden, prevalence of and risk factors for HTLV-II infection in injecting drug users of, 381
Syncytia formation, in HIV infection inhibition, 16

T cells
  in advanced HIV-1 infection, 61
  HIV-specific cytotoxic, sexual contact and (letter), 172
  proliferation of, 61, 257
  response of to gag peptides in natural HIV infection, 257
Tactile therapies, with antiretroviral or anti-opportunistic agents, 115
tax/rex-encoded mRNA, HTLV-I, 70
Tetanus toxoid, antibody response to, 5
TH epitopes, of gag peptides, 257
Thailand
  modified Amplicor HIV-1 polymerase chain reaction assay in (letter), 391
  molecular epidemiology of HIV-1 in, 304
Thalidomide, weight gain and (letter), 392
Therapeutic HIV vaccination, effect on HIV-1 proviral DNA and plasma RNA, 269
Toxoplasma encephalitis, prophylaxis against, 104
Transcription, of latent HIV-1 by *Mycobacterium tuberculosis* and PPD, 325
Trimethoprim-sulfamethoxazole, in *Pneumocystis carinii* pneumonia and toxoplasma encephalitis prophylaxis, 104

Uganda, vaccine acceptability and HIV-1 risk in, 375

Vaccine
  acceptability of in Ugandan military, 375
  proviral DNA characterization and, 247
  recombinant gp160 HIV-1, 269
  trials of, willingness to participate in among gay and bisexual men, 165
Vagina, HIV-1 specific immunoglobulin antibodies in secretion of, 185
Vertical transmission
  compliance with prenatal HIV testing and, 126
  sexual behavior and injection drug use during pregnancy and, 76
Viral load
  in disease progression (letter), 243
  with HTLV-I/HIV-1 coinfection, 308

in primary and chronic HIV-1 infection, 49
in semen, 54
therapeutic HIV vaccination and, 269
vitamin A supplementation effect on in pregnant women (letter), 86
Viral strain, HIV-1 progression and, 145
Vitamin A supplement, viral load in HIV-1-infected pregnant women and (letter), 86

Wasting, in men with HIV infection, 43
Weight gain, with thalidomide use (letter), 392
West Africa, HTLV-I and HTLV-II in pregnant women in (letter), 320
Women, clinical manifestations and predictors of survival in HIV-infected, 341

Zidovudine
absorption and elimination kinetics of in CSF, 192
administered two vs. six times daily, 283
in LFA-1 surface expression, 95
penetration of cytotoxic metabolites of into CSF of HIV-infected patients, 131